

Ian C Lawrance

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1815881/publications.pdf>

Version: 2024-02-01

30
papers

7,691
citations

394421

19
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

14346
citing authors

#	ARTICLE	IF	CITATIONS
1	Emu Oil Attenuates Disease Severity and Results in Fewer Large Colonic Tumors in a Mouse Model of Colitis-Associated Colorectal Cancer. <i>Nutrition and Cancer</i> , 2021, , 1-10.	2.0	3
2	Anti-TNF Therapy in Pregnant Women With Inflammatory Bowel Disease: Effects of Therapeutic Strategies on Disease Behavior and Birth Outcomes. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 93-102.	1.9	20
3	Orally administered emu oil attenuates disease in a mouse model of Crohn's-like colitis. <i>Experimental Biology and Medicine</i> , 2020, 245, 1697-1707.	2.4	5
4	The role of a plant-based diet in the pathogenesis, etiology and management of the inflammatory bowel diseases. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 137-145.	3.0	22
5	Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 273-280.	1.5	11
6	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 653-661.	1.3	22
7	Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer. <i>Digestive Diseases and Sciences</i> , 2018, 63, 135-145.	2.3	19
8	High Dose Vitamin D supplementation alters faecal microbiome and predisposes mice to more severe colitis. <i>Scientific Reports</i> , 2018, 8, 11511.	3.3	37
9	Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1248-1255.	4.4	53
10	Serologic antibodies in relation to outcome in postoperative Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1195-1203.	2.8	21
11	Performance of risk prediction for inflammatory bowel disease based on genotyping platform and genomic risk score method. <i>BMC Medical Genetics</i> , 2017, 18, 94.	2.1	36
12	Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. <i>Gastroenterology</i> , 2016, 151, 110-119.	1.3	259
13	Acute severe ulcerative colitis: Changing treatment paradigms. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 16-16.	2.8	0
14	The multidisciplinary team. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 17-17.	2.8	2
15	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet</i> , 2016, 387, 156-167.	13.7	607
16	Dysregulation of innate immunity in ulcerative colitis patients who fail anti-tumor necrosis factor therapy. <i>World Journal of Gastroenterology</i> , 2016, 22, 9104.	3.3	20
17	Animal Models of IBD-Associated CRC and Colorectal Cancer Tumorigenesis. <i>Clinical Medicine Insights Therapeutics</i> , 2015, 7, CMT.S18489.	0.4	3
18	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 452-462.	1.3	30

#	ARTICLE	IF	CITATIONS
19	Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet</i> , The, 2015, 385, 1406-1417.	13.7	475
20	Early investigational TNF receptor antagonists for the treatment of ulcerative colitis. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 761-768.	4.1	5
21	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. <i>Gastroenterology</i> , 2015, 148, 938-947.e1.	1.3	241
22	Results of the 4th scientific workshop of the ECCO (I): Pathophysiology of intestinal fibrosis in IBD. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1147-1165.	1.3	131
23	Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 598-606.	1.3	95
24	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	21.4	165
25	Crohn's disease and smoking: Is it ever too late to quit?. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e665-e671.	1.3	43
26	Oral Tacrolimus for the Treatment of Refractory Inflammatory Bowel Disease in the Biologic Era. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 1490-1498.	1.9	30
27	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	27.8	4,038
28	Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. <i>Nature Genetics</i> , 2011, 43, 246-252.	21.4	1,201
29	Serious infections in patients with inflammatory bowel disease receiving anti-tumor necrosis factor-alpha therapy: An Australian and New Zealand experience. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1732-1738.	2.8	78
30	Small bowel MRI enteroclysis or follow through: Which is optimal?. <i>World Journal of Gastroenterology</i> , 2009, 15, 5300.	3.3	19